The interpatient variability in response to asthma controllers is significant and associates with pharmacogenomic variability. The goal of the present study was to identify novel variants that associate with response to common asthma controllers: fluticasone, combination of fluticasone þ salmeterol and montelukast with single nucleotide polymorphisms (SNPs) in b2-adrenergic receptor, corticosteroid and leukotriene pathway candidate genes. Participants in a large clinical trial of step-down strategies volunteered for this pharmacogenetic study. A total of 169 SNPs in 26 candidate genes were genotyped in 189 Caucasian participants with asthma who took either fluticasone (100 mg bid), fluticasone propionate (100 mg) þ salmeterol (50 mg) (FP/Salm) or montelukast (5 or 10 mg) each night for 16 weeks. Primary outcomes were the slopes of plots of Asthma Control Questionnaire (ACQ) scores versus time following randomization; and the percent change in percent predicted FEV1 (DFEV1%pred) from enrollment to the end of the study. Associations between SNPs and outcomes were analyzed using general linear models. False discovery rate and Bonferroni corrections were used to correct for multiple comparisons. In all, 16 SNPs in seven genes were significantly associated with outcomes. For FP/Salm, three SNPs in CHRM2 associated with ACQ slope (P ¼ 2.8 Â 10
Introduction
Asthma is a chronic complex disease characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness and underlying inflammation. Asthma affects an estimated 20 million people in the United States and 300 million people worldwide, and its prevalence is rising. 1 There are a number of different drugs and drug classes that can be categorized as either bronchodilators or as controllers, and are effective and generally safe in controlling asthma symptoms. 2 The three most common classes of asthma controllers include inhaled corticosteroids (ICS), ICS in combination with long acting beta agonists (LABA) (ICS þ LABA) and leukotriene receptor antagonists either alone or in combination with ICS. Although effective, these drugs are associated with a significant degree of heterogeneity in patient response, which is due in large part to genetic variability. 3, 4 This is known from evaluation of the repeatability of asthma treatment response, 2, 5, 6 which is defined as the proportion of variance in a trait (FEV1, asthma exacerbations) that occurs between rather than within individuals.
Consistent with this understanding of the genetic basis for response heterogeneity, several polymorphisms have been associated with response to ICS, 7, 8 the combination of ICS and LABA, 9, 10 and leukotriene receptor antagonists [11] [12] [13] in different studies. Knowledge of sequence variants that influence response to asthma controller drugs is important because it can lead to personalizing asthma therapy and the development of novel drugs. At present, however, known sequence variants explain only a small fraction of the observed heterogeneity in response to asthma controller drugs. The goal of the present study was to identify novel variants that associate with response to common asthma controller drug therapy. A unique aspect of the present study is that we determine the pharmacogenetics of the three most common asthma controller drugs within the same study, providing a direct venue to compare pharmacogenetic response across therapies while increasing the specificity of our findings.
Materials and methods

Study design and patients
The present pharmacogenetic study was ancillary to a large clinical trial entitled: the Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol Trial (LOCCS NCT00156819).
14 Briefly, patients whose asthma was acceptably controlled with inhaled fluticasone proprionate (Flovent Diskus, Glaxo-SmithKline, Clifton, NJ, USA; 100 mg twice daily) were randomly assigned to receive double-blind treatment for 16 weeks with either continued inhaled fluticasone (100 mg twice daily), FP/Salm (100 mg fluticasone propionate þ 50 mg salmeterol, Advair Diskus, Glaxo-SmithKline, once daily) or montelukast (Singulair, Merck and Co., Whitehouse Station, NJ, USA; 6-14 year-old, 5 mg chewable tablet; X15 year-old, 10 mg capsule once daily). Acceptable control was defined as all of the following during the last 2 weeks of the fluticasone treatment run-in period: pre-bronchodilator FEV1 480% predicted; Asthma Control Questionnaire (ACQ) score o1.5; rescue b 2 -agonist use o16 puffs per week (excluding use as a premedication for exercise (one nebulizer use was considered equivalent to two puffs of b 2 -agonist); no hospitalization or unscheduled medical care visit for asthma; no oral corticosteroid use; no need for any additional asthma medication for asthma symptoms. All centers that participated in this ancillary study received approval from the relevant institutional review boards and all participants gave written informed consent before participation.
14 Treatments are subsequently referred to as fluticasone, FP/Salm or montelukast, respectively. In the present study, we report data from Caucasians only (64 FP/Salm, 65 fluticasone and 60 montelukast). Details of patient characteristics at enrollment and randomization from the parent trial can be found in the main manuscript. 14 In the parent trial, 64.2% of participants who received study treatment were Caucasian and 93.7% of those were non-Hispanic. Ethnicity of the participants in the pharmacogenomic study paralleled the parent trial, with 68.4% being Causacian and of those 93.1% were nonHispanic. Race or ethnic group was self-reported. A replicate cohort for the montelukast arm was obtained from a previous American Lung Association Asthma Clinical Research Centers (ALA-ACRC) study. 15 Outcomes Two outcomes were considered: the slope of the least squares regression line fit to a plot of scores from the ACQ 16 versus time at weeks 0, 2, 4, 8, 12 and 16 after randomization, and percent change in percent predicted FEV1(DFEV1%pred) (pre-bronchodilator) from enrollment to the end of the study (DFEV1%pred), defined as (%predicted FEV1 (week 16)-%predicted FEV1 (enrollment)/%predicted FEV1 (enrollment)) Â 100. Higher ACQ scores are indicative of asthma worsening. Predicted values for pulmonary function were calculated as described by Hankinson et al. 17 Prior to pulmonary function testing, all participants were instructed to withhold short-and long-acting b 2 -agonist drugs for 4 and 12 h, respectively. Recorded maneuvers had to meet criteria for acceptability (sharp start of flow volume curve; no cough within the first second; expiratory effort for at least 6 s) and reproducibility (the second largest FVC should be within 0.2 l of the largest acceptable FVC and the second largest FEV1 should be within 0.2 l of the largest acceptable FEV1). At least three acceptable and two reproducible efforts had to be obtained (up to a maximum of eight attempts), and the largest FEV1 and FVC were recorded.
Genotyping
Single nucleotide polymorphisms (SNPs) were genotyped by microsequencing of limited primer extension products as previously described. 8 P-values for deviation from HardyWeinberg equilibrium between observed and expected genotype distributions were calculated using an exact test, as described by Guo 21 for categorical variables or with analysis of variance 21 for continuous variables (Table 1 ).
Association analyses
We tested associations between individual SNPs and outcome phenotypes stratified by treatment using general linear models, as previously described. 8 The effect size was then calculated as the slope of the line between the adjusted means of the response variable for each genotype. Each model was adjusted for age, gender, height and height 2 . All analyses were performed in SAS V.9 (SAS Institute, Cary, NC, USA).
To compensate for the effects of multiple comparisons, we used the false discovery rate method of Storey and Tibshirani, 22, 23 as implemented in the R Statistical Package 24 computer program QVALUE (Princeton, NJ, USA). 23 We chose to limit the number of estimated false-positives to o1 within the results that are called significant. Additionally, we calculated the threshold P value for association significance using the Bonferroni correction, 21 which was 3.01 Â 10
À4
.
Results
Baseline characteristics of participants
Baseline characteristics of the Caucasian patients who participated in this study (189 total: 64 FP/Salm, 65 fluticasone and 60 montelukast) were not significantly different between the treatment groups ( Table 1 ). The one notable exception was the frequency of smoking, with significantly fewer individuals in the fluticasone treatment group having ever smoked, although total pack years was consistent among smokers of all treatment groups. This pattern was also evident in the clinical trial. 14 
Marker associations with pharmacodynamic outcomes
In total, 169 markers were genotyped in 26 candidate genes in the b 2 -adrenergic, corticosteroid and leukotriene pathways (Supplementary Tables E1 and E2 ). Three of the markers were monomorphic in our population and were not analyzed further. Genotype frequencies for five markers were not in Hardy-Weinberg equilibrium (Po0.05), including rs706765 in CPAMD8, rs1876831 in CRHR1, rs12319274 in HAL, rs2540483 in LTA4H and rs7941773 in STIP. Of these, only rs1876831 was found to be significantly associated with outcomes. The significant associations (16 markers in 7 genes) are summarized in Table 2 .
FP/Salm therapy
Three markers in CHRM2 (rs8191992, rs6962027 and rs6967953) were associated with ACQ slope for FP/Salm Predicted values for pulmonary function were calculated as described by Hankinson et al.
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Pharmacogenetics of asthma controllers EB Mougey et al ; Figure  1a and Table 2 ). As a consequence, by week 16, patients who were homozygous for the major allele had an ACQ score of 0.57±0.19 points compared with minor allele homozygotes who scored 0.93 ± 0.14 points (P ¼ 0.12, Figure 1b ).
An association between rs1461496 in HSPA8 and DFEV1%pred was observed for participants receiving FP/ Salm therapy (Figure 2 ). Participants homozygous for the minor allele had a 17% increase in adjusted mean DFEV1%pred compared with homozygous major allele participants (P ¼ 1.28 Â 10 À3 , Table 2 ). No associations with CHRM2 or HSPA8 were observed for either fluticasone or montelukast therapies (data not shown).
Fluticasone therapy
Five markers in CRHR1 (rs242941, rs739645, rs1876831, rs1876829 and rs1876828) were significantly associated with DFEV1%pred for participants receiving fluticasone therapy ( Table 2) . Four of the markers in CRHR1 were in LD (rs739645, rs1876831, rs1876829 and rs1876828), as previously reported. 25 Patients who were homozygous for the minor alleles showed an improvement of 24.2±9.10% in adjusted mean DFEV1%pred between enrollment and week 16 of treatment compared with 10.1 ± 2.67% for heterozygotes and 2.98±1.88% for major allele homozygotes (P ¼ 1.89 Â 10 À4 ; Figure 3 and Table 2 ). Conversely, CRHR1 rs242941 was associated with decreased DFEV1%pred. By week 16, patients homozygous for rs242941 scored 18.3 ± 5.59% lower than patients who were homozygous for the major allele (P ¼ 2.07 Â 10 À3 ; Figure 3 and Table 2 ), suggesting that DFEV1%pred in these patients was not protected by fluticasone therapy and in fact deteriorated over the course of the trial to finish at a value lower than that recorded at enrollment.
The recessive model identified a novel association between three markers in COL2A1 (rs2276458, rs2276455 and resulting in a differential of 14.5 ± 2.37% between homozygous major and homozygous minor allele patients (P ¼ 4.25 Â 10 À3 ; Figure 4 and Table 2 ).
Montelukast therapy
The linked markers in CRHR1: rs739645, rs1876831, rs1876829 and rs1876828 were associated with DFEV1%pred for montelukast therapy; however, the effect observed was opposite in direction to that seen for fluticasone therapy (adjusted mean DFEV1%pred effect size for fluticasone versus montelukast therapy ¼ 10.4 ± 1.40% versus À6.26 ± 1.19, Table 2 and Figures 3 and 5) . Patients homozygous for the major allele improved by 4.6±1.8% whereas patients who were homozygous for the minor allele showed no improvement over that recorded at enrollment (P ¼ 8.6 Â 10 À3 ; Figure 5 and Table 2 ). CRHR1 marker rs242950, which is not in LD with rs739645, rs1876831, rs1876829 and rs1876828, associated with ACQ slope for participants receiving montelukast therapy. In rs242950 heterozygotes, ACQ slope was negative, indicating reduced asthma symptoms whereas ACQ slope for major allele homozygotes was positive, indicating increased asthma symptoms (P ¼ 3.57 Â 10 À3 ; Figure 6 and Table 2 ). Mean ACQ scores ( ± s.e.) in homozygotes and heterozygotes at week 16 were 0.963 ± 0.109 and 0.543±0.087, respectively (P ¼ 0.075).
In an attempt to evaluate the validity of the associations between response to montelukast and genotype at rs739645, rs1876831, rs1876829 and rs1876828 in CRHR1, we determined associations between rs1876829 and response (DFEV1%pred, ACQ scores) in a replicate cohort from a previous study. 15 No associations were observed between genotype at rs1876829 and DFEV1%pred. However, the mean ACQ scores ( ± s.e.) in major allele homozygous participants and heterozygotes were 1.65±0.11 and 1.21±0.17, respectively, following 1 month of montelukast treatment (P ¼ 0.049). ACQ scores following 6 months of treatment also trended in this same direction: 1.55 ± 0.12 and 1.23±0.16, respectively (P ¼ 0.21).
One additional marker, rs3757016 in histone deacetylase 2 (HDAC2) (Figure 7 ) was associated with significant improvement in DFEV1%pred for montelukast therapy ( Table 2) . Compared with major allele homozygotes, heterozygotes and/or homozygotes for the minor allele were associated with improved DFEV1%pred in participants receiving montelukast therapy. Figure 4 Association between genotype of Markers in COL2A1 and pulmonary function for fluticasone treatment. Mean percent changes in percent-predicted FEV1 ( ± s.e.) were calculated between week 16 and visit 1 (randomization) in participants taking fluticasone treatment by genotype for rs2276458 ( ), rs2276455 ( ) and rs2276454 ( ). MM refers to homozygous for the major alleles, mM refers to heterozygotes and mm refers to homozygotes for the minor alleles. Figure 5 Association between genotype of markers in CRHR1 and pulmonary function for montelukast treatment. Mean percent changes in percent-predicted FEV1 ( ± s.e.) were calculated between week 16 and visit 1 (randomization) in participants taking montelukast by genotype for rs739645( ), rs1876831 ( ), rs1876829 ( ) and rs1876828 ( ). MM refers to homozygous for the major alleles, mM refers to heterozygotes and mm refers to homozygotes for the minor alleles. Figure 6 Association between rs242950 in CRHR1 and Asthma Control Questionnaire (ACQ) scores for montelukast treatment. Mean slopes of the regression line of scores from the ACQ ( ± s.e.) versus time were compared with genotype for rs242950 ( ) in participants taking montelukast for 16 weeks. MM refers to homozygous for the major allele and mM refers to heterozygotes.
Discussion
Among the novel associations that we identified were three SNPs in CHRM2 and a single SNP in HSP8A that associated with response to FP/Salm therapy, and five SNPs in CRHR1 and a single SNP in HDAC2 that associated with response to montelukast therapy. Five SNPs in CRHR1 replicated results in previous studies with ICS. Of particular interest was the observation that CRHR1 variants were inversely associated with differential improvement in lung function, following fluticasone and montelukast therapies (Figures 3 and 5) . To our knowledge, this study is the first to report that associations between genetic variants and response to ICS and leukotriene receptor antagonists are inversely related, thus potentially providing a genetic rationale for selecting one controller over the other.
FP/Salm therapy
The strongest pharmacogenetic association we observed was between three SNPs in CHRM2, which are in LD (see Supplementary Figure E1 ), and ACQ slope following treatment with FP/Salm (Figure 1a ). Autonomic control of airway tone in humans is primarily mediated by acetylcholine released from parasympathetic nerves. 26 Acetylcholine exerts its effect by stimulation of muscarinic receptors (M1-M5) expressed on airway smooth muscle, submucosal glands, blood vessels and nerves. [27] [28] [29] M2 mAChR expressed on prejunctional, postganglionic parasympathetic nerves, functions to attenuate synaptic acetylcholine release through negative feedback, 30, 31 and loss of this control contributes to increased airway tone and hyperreactivity in asthma and chronic obstructive pulmonary disease. 32, 33 Conversely, postjunctional M2 mAChR expressed on smooth muscle can inhibit b 2 -adrenoceptor-induced bronchodilation. [34] [35] [36] M3 mAChR expressed on airway smooth muscle and submucosal glands facilitates smooth muscle contraction [37] [38] [39] and mucus secretion, [40] [41] [42] respectively. b-adrenoceptors and muscarinic receptors expressed in human airway smooth muscle can influence each other through receptor cross talk. 43 The use of ICS þ LABA in asthma is controversial; 44 some studies report that continued LABA use even in the presence of ICS can make asthma symptoms worse. 10, 45, 46 Several studies have reported that individuals carrying the Arg16 allele of the ADRB2 are more susceptible to the negative effects of continuous b 2 -adrenoceptor stimulation compared with carriers of the Gly16 allele. [47] [48] [49] We observed no association between ACQ slope and ADRB2 variants in participants taking FP/Salm. However, given the potential of receptor cross talk between b 2 -adrenoceptors and M2 mAChR in airways, and the association between ACQ scores and CHRM2 variants, it is important to replicate our findings in future studies.
Fluticasone therapy
The linked CRHR1 SNPs rs1876831, rs1876828, rs739645 and rs1876829 were strongly associated with DFEV1%pred in patients receiving fluticasone (8.2-fold higher for minor allele homozygotes, Figure 5 ). rs242941 was associated with a negative DFEV1%pred compared with major allele homozygotes and heterozygotes ( Figure 3 ). These data replicate results of our previous studies in asthma 8, 50 and in chronic obstructive pulmonary disease, at least for rs242941, 51 indicating that CRHR1 is an important gene in modulating the effects of ICS. SNPs in CRHR1 have also been associated with markers of inflammation and endothelial dysfunction in elderly males with asthma and/or chronic obstructive pulmonary disease. 52 Corticotropin-releasing hormone binds to CRHR1 and exerts its antiinflammatory effects by mediating the release of adrenocorticotropic hormone and promoting the production of cortisol. 53 Thus, variants of CRHR1 could affect corticotropin-releasing hormone binding and subsequently adrenocorticotropic hormone release, airway inflammation and responsiveness to ICS. 8 Alternatively, the associations between ICS responsiveness in asthma and CRHR1 variants may be related to a large inversion polymorphism. 25 
Montelukast therapy
The association between CRHR1 SNPs rs1876831, rs1876828, rs739645, rs1876829 and DFEV1%pred in patients receiving montelukast was the inverse of that observed for patients receiving fluticasone. We were not able to replicate this association in a cohort of participants who received montelukast in a previous study (LODO 15 ). Interestingly, ACQ scores for heterozygotes at rs1876828 in LODO participants taking montelukast were lower, following 1 month of therapy compared with placebo (1.21 ± 0.17 versus 2.00±0.19; analysis of variance P ¼ 0.012, two-sided Dunnet P ¼ 0.007), whereas ACQ scores in major allele homozygotes were not significantly different from placebo (1.65 ± 0.11 versus 1.88 ± 0.14; analysis of variance P ¼ 0.41). This pattern was not, however, evident following 6 months of treatment (data not shown). These data are not consistent with our findings in the present study.
HDAC2 SNP rs3757016 was associated with a significant improvement in DFEV1%pred for patients receiving montelukast ( Figure 7) . HDAC2 contributes to suppression of inflammatory gene expression, and is thought to have a major role in corticosteroid resistance, 15, 54, 55 which Figure 7 Association between genotype of histone deacetylase 2 (HDAC2) and pulmonary function for montelukast. Mean percent changes in percent-predicted FEV1 (±s.e.) were calculated between week 16 and visit 1 (randomization) in participants taking montelukast by genotype for rs3757016 in HDAC2. MM refers to homozygous for the major alleles, mM refers to heterozygotes and mm refers to homozygotes for the minor alleles.
potentially may be reversed by increasing HDAC2 activity. 56 The mechanism underlying the association between rs3757016 and DFEV1%pred in participants taking montelukast is not clear. However, if rs3757016 is associated with gain of HDAC2 function, then attenuation of inflammatory gene expression would increase with allele dosage, conceivably leading to increased effectiveness of montelukast.
Our study has several limitations, including a small number of participants which limited our power to detect associations between response and SNPs with minor allele frequencies o0.1. To avoid population stratification, we limited our study to Caucasians because of the small number of African Americans and other ethnicities who participated. We have limited access to other pharmacogenetic studies that impeded our ability to replicate our novel associations.
In conclusion, we believe the results of our study strongly support the inclusion of pharmacogenomics in comparative effectiveness research and personalized medicine.
Conflict of interest
Edward Mougey and John Lima received funding from Merck to characterize associations between transporter SNPs, and the pharmacokinetics and pharmacodynamics of montelukast. Stephen Peters received compensation as a consultant to the ALA-ACRC DCC. Robert Wise received compensation as a consultant to the following companies: Astra Zeneca, Boehringer-Ingelheim, GSK, Novartis, Sunovion, Centocor, Genentech, Medimmune, Intermune and Pfizerone. Dr Wise is also funded by the following companies: Boehringer-Ingelheim, GSK, Merck Forest.
